El–Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. https://doi.org/10.1053/j.gastro.2007.04.061.

Article  CAS  PubMed  Google Scholar 

Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomark Prev. 2011;20:2362–8. https://doi.org/10.1158/1055-9965.EPI-11-0643.

Article  Google Scholar 

Liu C-Y, Chen K-F, Chen P-J. Treatment of liver cancer. Cold Spring Harb Perspect Med. 2015;5:a021535. https://doi.org/10.1101/cshperspect.a021535.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. The Lancet. 2007;369:1603–13. https://doi.org/10.1016/S0140-6736(07)60747-8.

Article  CAS  Google Scholar 

Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis. BMJ 2016;i6188. https://doi.org/10.1136/bmj.i6188.

Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial. The Lancet. 2020;395:1855–63. https://doi.org/10.1016/S0140-6736(20)30366-4.

Article  CAS  Google Scholar 

Liao Y-H, Hsu R-J, Wang T-H, et al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: A nationwide cohort study. BMC Gastroenterol. 2020;20:6. https://doi.org/10.1186/s12876-020-1158-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology hep. 2022;32380. https://doi.org/10.1002/hep.32380.

Yun B, Ahn SH, Yoon JH, Kim BK. Clinical indication of aspirin associated with reduced risk of liver cancer in chronic hepatitis B: A nationwide cohort study. Am J Gastroenterol. 2022;117:758–68. https://doi.org/10.14309/ajg.0000000000001725.

Article  CAS  PubMed  Google Scholar 

Hui VWK, Yip TCF, Wong VWS, et al. Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog. Clin Transl Gastroenterol. 2021;12:e00324. https://doi.org/10.14309/ctg.0000000000000324.

Article  PubMed  PubMed Central  Google Scholar 

Simon TG, Duberg A-S, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382:1018–28. https://doi.org/10.1056/NEJMoa1912035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stroup DF. Meta-analysis of observational studies in epidemiology A proposal for reporting. JAMA. 2000;283:2008. https://doi.org/10.1001/jama.283.15.2008.

Article  CAS  PubMed  Google Scholar 

Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787. https://doi.org/10.1001/jamasurg.2021.0522.

Article  PubMed  Google Scholar 

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5. https://doi.org/10.1007/s10654-010-9491-z.

Article  PubMed  Google Scholar 

Lee C-H, Hsu C-Y, Yen T-H, et al. Daily aspirin reduced the incidence of hepatocellular carcinoma and overall mortality in patients with cirrhosis. Cancers. 2023;15:2946. https://doi.org/10.3390/cancers15112946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee C, Lee YB, Moon H, et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023;58:704–14. https://doi.org/10.1111/apt.17643.

Article  CAS  PubMed  Google Scholar 

Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci Rep. 2018;8:4968. https://doi.org/10.1038/s41598-018-23343-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho C-M, Lee C-H, Lee M-C, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study. BMC Cancer. 2018;18:401. https://doi.org/10.1186/s12885-018-4292-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi W, Kim HJ, Jo AJ, et al. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int. 2021;41:2777–85. https://doi.org/10.1111/liv.15011.

Article  CAS  PubMed  Google Scholar 

Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology. 2022;76:492–501. https://doi.org/10.1002/hep.32380.

Article  CAS  PubMed  Google Scholar 

Lee M, Chung GE, Lee J, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017;66:1556–69. https://doi.org/10.1002/hep.29318.

Article  CAS  PubMed  Google Scholar 

Lee T-Y, Hsu Y-C, Tseng H-C, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med. 2019;179:633. https://doi.org/10.1001/jamainternmed.2018.8342.

Article  PubMed  PubMed Central  Google Scholar 

Lee T-Y, Hsu Y-C, Tseng H-C, et al. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18:2784-2792.e7. https://doi.org/10.1016/j.cgh.2020.04.036.

Article  CAS  PubMed  Google Scholar 

McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis. 2011;15:223–43. https://doi.org/10.1016/j.cld.2011.03.006.

Article  PubMed  PubMed Central  Google Scholar 

Fodera D. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci. 2004;1028:440–9. https://doi.org/10.1196/annals.1322.052.

Article  CAS  PubMed  Google Scholar 

Leng J. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68. https://doi.org/10.1053/jhep.2003.50380.

Article  CAS  PubMed  Google Scholar 

Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepatitis. 2009;16:453–63. https://doi.org/10.1111/j.1365-2893.2009.01117.x.

Article  CAS  Google Scholar 

Ganem D. Hepatitis B virus infection — Natural history and clinical consequences. N Engl J Med. 2004;12.

Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis. 2006;1:23–61. https://doi.org/10.1146/annurev.pathol.1.110304.100230.

Article  CAS  Google Scholar 

Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nat Med. 2005;11:1167–9. https://doi.org/10.1038/nm1317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. ATVB. 2004;24:1980–7. https://doi.org/10.1161/01.ATV.0000145980.39477.a9.

Article  CAS  Google Scholar 

Zhang H, Yang S, Wang J, Jiang Y. Blockade of AMPK-mediated cAMP–PKA–CREB/ATF1 signaling synergizes with aspirin to inhibit hepatocellular carcinoma. Cancers. 2021;13:1738. https://doi.org/10.3390/cancers13071738.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trujillo-Murillo K, Rincón-Sánchez AR, Martínez-Rodríguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology. 2008;47:1462–72. https://doi.org/10.1002/hep.22215.

Article  CAS  PubMed  Google Scholar 

Ríos-Ibarra CP, Lozano-Sepulveda S, Muñoz-Espinosa L, et al. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. Arch Virol. 2014;159:3321–8. https://doi.org/10.1007/s00705-014-2201-5.

Article  CAS  PubMed  Google Scholar 

Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J Viral Hepat. 2016;23:62–4. https://doi.org/10.1111/jvh.12446.

Article  CAS  PubMed  Google Scholar 

Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109. https://doi.org/10.1073/pnas.1209182109.

Article  PubMed